On November 23rd, the second "Entrepreneurship Yimeng, Win Win Future" high-level talent entrepreneurship competition, hosted by the Organization Department of the Communist Party of China Linyi Municipal Committee, Linyi Science and Technology Bureau, and Linyi Municipal Talent Development Service Center, came to a successful conclusion. Dr. Tan Shengwei, founder of Suzhou Linaxin Biotechnology Co., Ltd., applied for the project of "Research and Industrialization of Multi gene Mutation Combined with Methylation Synergistic Effect Colorectal Cancer Early Screening Product", which won the third prize.

Lichangsheng, independently developed by Linaxin Biotechnology, is a major technological breakthrough in the early screening industry for cancer. This product is based on fluorescence quantitative PCR and immune technology, and evaluates cancer risk through colorectal cancer related gene mutations and fecal occult blood testing, with high sensitivity and specificity. Compared to traditional colonoscopy, Lichangsheng has advantages such as home sampling, painless and non-invasive, and non-invasive privacy protection, which can help improve the coverage of colorectal cancer screening, bridge the last mile of early screening, and promote the achievement of the "Healthy China Action - Cancer Prevention and Control Action" goal.